Marijuana Moment

4 days ago | marijuanamoment.net | Kyle Jaeger

Seven in 10 American voters want to see the end of federal marijuana prohibition—and nearly half say they’d view the Trump administration more favorably if it took action on the issue—according to a new poll. The survey, commissioned by the Coalition for Cannabis Policy, Education, and Regulation (CPEAR) and conducted by the firm Forbes Tate Partners, asked a series of questions to gauge public opinion about cannabis policy issues.

5 days ago | marijuanamoment.net | Kyle Jaeger

The Republican governor of Texas has vetoed a bill that would have banned consumable hemp products with any traces of THC that advocates and stakeholders say would have decimated a growing industry in the state. Gov. Greg Abbott (R) rejected the legislation, SB 3 from Sen. Charles Perry (R), on Sunday. This comes after weeks of uncertainty around how the governor would approach the bill, which was championed by Lt. Gov.

5 days ago | marijuanamoment.net | Alander Rocha

The lab will be the only medical cannabis testing lab in the state until AMCC reopens the application process. By Alander Rocha, Alabama ReflectorThe Alabama Medical Cannabis Commission (AMCC) voted Tuesday to award Foley-based Green Health Laboratories a state testing laboratory license.

6 days ago | marijuanamoment.net | Kyle Jaeger

The governor of Texas has approved a bill to to significantly expand the state’s medical marijuana program. As advocates and stakeholders await the fate of a separate measure banning consumable hemp products, Gov. Greg Abbott (R) on Saturday signed into law the medical cannabis legislation from Rep. Ken King (R).

1 week ago | marijuanamoment.net | Kyle Jaeger

Taking a high dose of LSD, coupled with assisted therapy, led to “greater reductions in depression” among patients compared to those who received a low dose of the psychedelic, according to a new study. Researchers at the University of Basel in Switzerland investigated the therapeutic potential of LSD for people with moderate-to-severe major depressive disorder, and they found the substance showed “promise” as a “novel approach” to treating the condition.